NOVAVAX Revenue and Competitors
Estimated Revenue & Valuation
- NOVAVAX's estimated annual revenue is currently $1.2B per year.
- NOVAVAX's estimated revenue per employee is $902,256
- NOVAVAX's total funding is $2.4B.
- NOVAVAX's current valuation is $8.4B. (January 2022)
Employee Data
- NOVAVAX has 1330 Employees.
- NOVAVAX grew their employee count by -6% last year.
NOVAVAX's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr VP Vaccine Development and Chief Scient | Reveal Email/Phone |
2 | Executive Assistant to VP Strategic Alliances | Reveal Email/Phone |
3 | Sr. VP, Global Supply Chain & Strategic Sourcing | Reveal Email/Phone |
4 | VP, Global Business Technology | Reveal Email/Phone |
5 | SVP | Reveal Email/Phone |
6 | VP, Head Global Medical Writing and Clinical Trial Transparency | Reveal Email/Phone |
7 | SVP, Global Program Management | Reveal Email/Phone |
8 | VP Facilities and Engineering | Reveal Email/Phone |
9 | VP, Global Risk Management Global Vaccine Safety | Reveal Email/Phone |
10 | SVP, Government Affairs, Market Access and Alliances | Reveal Email/Phone |
NOVAVAX Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $69340M | 107310 | 4% | N/A | $308.4B |
#2 | $141.7M | 351 | 6% | N/A | N/A |
What Is NOVAVAX?
Novavax AB is a fully owned subsidiary of Novavax Inc. a late-stage biotechnology company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. Our recombinant nanoparticles and Matrix-Mￃﾢ￢ﾀﾞￂﾢ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("RSV"), seasonal influenza, pandemic influenza, and Ebola virus ("EBOV"). We have additional preclinical-stage programs for a variety of infectious diseases. Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
keywords:N/A
$2.4B
Total Funding
1330
Number of Employees
$1.2B
Revenue (est)
-6%
Employee Growth %
$8.4B
Valuation
N/A
Accelerator
NOVAVAX News
Novavax signaled a positive outlook for its vaccine pipeline Wednesday with announcements at the World Vaccine Congress and an update on its...
Japan's health ministry on Tuesday formally approved Novavax's COVID-19 vaccine, a fourth foreign-developed tool to combat the infections as...
A Japanese Health Ministry committee said on Monday it has approved Novavax Inc's COVID-19 vaccine, setting the stage for full approval of...
SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation ...
GAITHERSBURG, Md., Nov. 4, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended ...
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1650M | 2355 | -18% | $36.5M |
#2 | $1113.6M | 3867 | 5% | N/A |
#3 | $706.1M | 4945 | N/A | N/A |
#4 | $718.4M | 5031 | 6% | N/A |
#5 | $2188M | 6153 | 7% | N/A |